Seeking Alpha

Fresh off its acquisition of Obagi Medical, Valeant Pharmaceuticals (VRX) is reportedly in talks...

Fresh off its acquisition of Obagi Medical, Valeant Pharmaceuticals (VRX) is reportedly in talks to buy Actavis (ACT) for $13B in a deal billed as a "merger of equals" that would pay ACT shareholders a slight premium. Earlier this month, the two companies settled patent litigation surrounding NDA applications for generic versions of Zyclara and Ziana. Asked for comment, a Valeant spokesperson tells WSJ only: "We're a very acquisitive company."
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs